Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced it has acquired Vector Laboratories (Vector), the Protein Detection business unit of Maravai (NASDAQ: MRVI). Vector Laboratories is a manufacturer of labeling and visual detection reagents for life science researchers doing tissue-based protein detection and characterization. The acquisition of Vector adds to TSCP’s experience in life sciences. Terms of the transaction were not disclosed.
“Maravai has been critical in helping strengthen Vector Laboratories’ operations, including innovative solutions to better serve our academic and early development stage customers,” said Lisa V. Sellers, Ph.D., Vector’s Chief Executive Officer. “We’re excited to partner with Thompson Street Capital Partners, as their knowledge of the research reagents space provides an immediate opportunity to position the Company for both organic and strategic growth and take advantage of what we believe are tremendous opportunities in the marketplace.”
Vector Laboratories provides consumable reagents used in slide staining and imaging workflows within life science research, allowing scientists to better locate and identify certain proteins within a tissue sample. Vector’s primary end markets are academic research labs and corporations, provided either directly to customers or via distributors and resellers.
“Vector Laboratories has been an established, well-respected and innovative manufacturer in the life science sector for decades, and we’re excited to be partnering with Dr. Sellers and the Vector team to achieve the next phase of the Company’s growth,” said Bob Dunn, Managing Partner at TSCP. Added J.C. Wetzel, Director at TSCP, “Our experience in the life sciences sector allows us to understand the importance of what Vector provides to its customers as well as recognize the long-term potential for continued evolution.”
